Pancreatic Cancer Genetics

Overseen By Vilma Rosario

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Columbia University

Disqualifiers: Under 18, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

100 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The aim of this study is to determine the frequency of the three most common BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genetic mutations that are commonly found in Ashkenazi Jewish patients with pancreatic cancer. Testing for BRCA1 and BRCA2 mutations in relatives of hereditary pancreatic cancer patients may have a significant impact; allowing for early screening, treatment, and resection of pre-malignant tissue or malignant lesions.

Who Is on the Research Team?

Fay Kastrinos, MD

Principal Investigator

Columbia University

Are You a Good Fit for This Trial?

Inclusion Criteria

Patients diagnosed with pancreatic cancer.

Patients are of Ashkenazi Jewish descent.

Patients have been Columbia Pancreatic Cancer Prevention Program Registry and Tissue Bank for High-Risk Individuals (IRB-AAAA6154).

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Genetic Testing

Participants undergo genetic testing to determine the frequency of BRCA1 and BRCA2 mutations

1 year

Follow-up

Participants are monitored for safety and effectiveness after genetic testing

4 weeks

What Are the Treatments Tested in This Trial?

Who Is Running the Clinical Trial?

Columbia University

Lead Sponsor

Trials

1,529

Recruited

2,832,000+